Adult umbilical cord blood transplantation: a comprehensive review
- 5 June 2006
- journal article
- review article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 38 (2) , 83-93
- https://doi.org/10.1038/sj.bmt.1705403
Abstract
Recent registry studies have established umbilical cord blood (UCB) transplantation as a safe and feasible alternative to bone marrow transplantion in adults when no sibling donor is available. There is, however, no gold standard to guide optimal treatment choices. We review here factors leading to the choice of the ‘best available donor’ and ‘best available unit’ in the case of UCB. For instance, it is clear that higher cell dose may partially overcome the negative impact of certain histocompatibility leukocyte antigen (HLA) disparities in UCB transplantation, leading us to choose the more closely HLA-matched unit with a cell dose >2.5 × 107/kg. New approaches in adult UCB transplantation are systematically covered, with a quantitative appreciation of the evidence available to date. Reduced intensity conditioning, for example, broadens the range of potential recipients by reducing transplant-related mortality, but suffers from unproven risks and benefits long term. Potential advantages of multiple units over single unit transplants are discussed, with a particular emphasis on confounding factors that impact interpretation. The limited clinical results of ex vivo UCB expansion, the possible benefits of co-infusion of haploidentical cells and controversial issues (e.g. killer immunoglobulin-like receptor matching and alternative graft sources) are also addressed with a debate on the future of UCB transplantation.Keywords
This publication has 53 references indexed in Scilit:
- 15. Augmentation of homing of cord blood stem cellsTransplantation and Cellular Therapy, 2005
- 5. Comparison of adult allogeneic umbilical cord blood transplantation between myeloablative and non-myeloablative conditioning regimensTransplantation and Cellular Therapy, 2005
- 2. Cord blood transplantation to adult patients: A New York blood center updateTransplantation and Cellular Therapy, 2005
- 13. In vivo stem cell factor (R-MetHuSCF) and filgrastim administration after unrelated UCB transplantation in adultsTransplantation and Cellular Therapy, 2005
- 8. Unrelated single cord blood transplants supported by co-infusion of a low number of mobilized peripheral blood highly purified CD34+ cells from a third party donor after low toxicity myeloablative conditioningTransplantation and Cellular Therapy, 2005
- Cord Blood Immunology and Stem Cell TransplantationHuman Immunology, 2005
- Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimensTransplantation and Cellular Therapy, 2004
- Augmentation of umbilical cord blood (UCB) transplantation with ex vivo–expanded UCB cells: results of a phase 1 trial using the AastromReplicell SystemBlood, 2003
- Impact of stem cell donation modality on normal donor quality of life: a prospective randomized studyBone Marrow Transplantation, 2003
- Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institutionBone Marrow Transplantation, 2001